Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 2, 2011, Pages 563-570

  Heyerdahl, Helen ^a   Krogh, Cecilie ^a   Borrebæk, Jørgen ^b   Larsen, Smund ^a,b   Dahle, Jostein ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Algeta ASA   (Norway)

Author keywords

Alpha particle radiation; Breast cancer; Ovarian cancer; Radioimmunotherapy; Thorium 227

Indexed keywords

ABSORBED RADIATION; ACTIVITY CONCENTRATION; APOPTOSIS; BREAST CANCER; BREAST CANCER CELLS; CELL LINES; CELL SURFACES; CLONOGENIC SURVIVAL; CYTOTOXIC EFFECTS; DOSE-DEPENDENT; LOW DOSE RATE; METASTATIC CANCERS; OVARIAN CANCER CELLS; OVARIAN CANCERS; PARTICLE RADIATION; RADIATION DOSE; RADIOIMMUNOTHERAPY; RELATIVE BIOLOGICAL EFFECTIVENESS; SINGLE-DOSE; TETRAACETIC ACID; THERAPEUTIC AGENTS; TIME POINTS; TRASTUZUMAB; X-RADIATION;

ALPHA PARTICLES; CELL CULTURE; CELL DEATH; CELL GROWTH; CELL MEMBRANES; DOSIMETRY; GROWTH (MATERIALS); GROWTH KINETICS; MONOCLONAL ANTIBODIES; RADIATION; THORIUM;

RADIOTHERAPY;

4 ISOTHIOCYANATO BENZYL 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TRASTUZUMAB TH 227; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RITUXIMAB; RITUXIMAB TH 227; TRASTUZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL SURVIVAL; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOCONJUGATES; NEOPLASM PROTEINS; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; RADIOTHERAPY DOSAGE; RECEPTOR, ERBB-2; RELATIVE BIOLOGICAL EFFECTIVENESS; TUMOR STEM CELL ASSAY;

EID: 78650832958     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.08.038     Document Type: Article

References (14)

1. G. Sgouros, A.M. Ballangrud, and J.G. Jurcic Pharmacokinetics and dosimetry of an alpha particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia J Nucl Med 40 1999 1935 1946
2. D.J. Slamon, G.M. Clark, and S.G. Wong Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
3. D. Gancberg, A. Di Leo, and F. Cardoso Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 13 2002 1036 1043
4. M.A. Bookman, K.M. Darcy, D. Clarke-Pearson, R.A. Boothby, and I.R. Horowitz Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group J Clin Oncol 21 2003 283 290
5. G. Akabani, S. Carlin, P. Welsh, and M.R. Zalutsky In vitro cytotoxicity of (211)At-labeled trastuzumab in human breast cancer cell lines: Effect of specific activity and HER2 receptor heterogeneity on survival fraction Nucl Med Biol 33 2006 333 347
6. A.C. Steffen, L. Gostring, V. Tolmachev, S. Palm, B. Stenerlow, and J. Carlsson Differences in radiosensitivity between three HER2 overexpressing cell lines Eur J Nucl Med Mol Imaging 35 2008 1179 1191
7. E. Horak, F. Hartmann, and K. Garmestani Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1 J Nucl Med 38 1997 1944 1950
8. 227Th- p-benzyl-DOTA-rituximab for low-dose rate alpha particle radioimmunotherapy Nucl Med Biol 33 2006 271 279
9. J. Dahle, J. Borrebaek, and T.J. Jonasdottir Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate Blood 110 2007 2049 2056
10. 227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability Cancer Biother Radiopharm 22 2007 431 437
11. J.C. Roeske, and M. Hoggarth Alpha-particle Monte Carlo simulation for microdosimetric calculations using a commercial spreadsheet Phys Med Biol 52 2007 1909 1922
12. 227-DOTA-rituximab Int J Radiat Oncol Biol Phys 75 3 2009 886 895
13. S. Nilsson, L. Franzen, and C. Parker Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Lancet Oncol 8 2007 587 594
14. 227)Th-rituximab Eur J Nucl Med Mol Imaging 37 2010 93 102